Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Ravdin

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Population-based validation of the prognostic model ADJUVANT! for early breast cancerIvo A Olivotto, Chris D Bajdik, Peter M Ravdin, et al.
The Lancet. Oncology|October 6, 2009
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort studyStella Mook, Marjanka K Schmidt, Emiel J Rutgers, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2011
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phaseEmiel Rutgers, Martine J Piccart-Gebhart, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresLori J Goldstein, Robert Gray, Sunil Badve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
The New England Journal of Medicine|February 7, 2009
Breast cancer after use of estrogen plus progestin in postmenopausal womenRowan T Chlebowski, Lewis H Kuller, Ross L Prentice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trialJi-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Breast Cancer Research and Treatment|March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Population-based validation of the prognostic model ADJUVANT! for early breast cancerIvo A Olivotto, Chris D Bajdik, Peter M Ravdin, et al.
The Lancet. Oncology|October 6, 2009
Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort studyStella Mook, Marjanka K Schmidt, Emiel J Rutgers, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2011
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phaseEmiel Rutgers, Martine J Piccart-Gebhart, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresLori J Goldstein, Robert Gray, Sunil Badve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
The New England Journal of Medicine|February 7, 2009
Breast cancer after use of estrogen plus progestin in postmenopausal womenRowan T Chlebowski, Lewis H Kuller, Ross L Prentice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trialJi-Yeob Choi, William E Barlow, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Breast Cancer Research and Treatment|March 24, 2010
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancerSong Yao, William E Barlow, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Pageof 4